Hot Stocks: RF Micro Devices, Molycorp, Wells Fargo & Co, ZIOPHARM Oncology

Lakeway, NY -- (SBWIRE) -- 03/18/2013 -- ThePennyStockProfiler.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-

RF Micro Devices, Inc. (NASDAQ:RFMD) stock increased 3.34% to $4.98. The company, on Mar. 15, announced it has been selected by a leading smartphone manufacturer to supply multiple 3G/4G LTE components into a recently announced fourth-generation flagship smartphone platform. The highly anticipated smartphones will feature RFMD's recently announced RF7388 multimode multi-band (MMMB) 3G/4G PA, multiple variants of RFMD's RF73xx family of ultra-high efficiency LTE PAs, and RFMD's industry-leading antenna control solutions.

Is RFMD a Strong Buy After The Recent Slump? Let’s Find out Here

Molycorp Inc (NYSE:MCP) shares increased 3.34% to $6.19. The company, on Mar. 14, reported a fourth quarter loss of $359.6 million, or $2.91 a share, in the quarter ended Dec. 31. That compared with net income of $26.6 million, or 26 cents a share, in the year-ago period. Adjusted loss was $52.7 million, or 45 cents a share, compared with an adjusted profit of $35.9 million, or 41 cents a share. Revenue rose 1 percent to $134.3 million.

Is MCP a Strong Buying Opportunity After The Recent Slump? Find out Here

Wells Fargo & Co(NYSE:WFC) shares increased 3.33% to $38.20. The company on Mar. 15 announced that the Federal Reserve has not objected to the company’s 2013 capital plan. WFC now plans to raise its quarterly dividend from 25 cents to 30 cents per share. This dividend will be paid in the second quarter of 2013 and is subject to the approval of the company’s board.

Additionally, the company declared today that seven of its funds were recipients of 2013 Lipper Fund Awards for consistent returns. Six of the seven funds recognized are multi-year Lipper Fund Award winners, including the Wells Fargo Advantage Growth Fund and two national municipal fixed-income funds and its stepped-up commitment to these entrepreneurs by increasing its lending target to $55 billion by the year 2020.

Should Investors Consider WFC After The Recent price Action? Get Free Trend Analysis Here

ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) shares climbed 3.31% and closed at $5.61. The company, on Mar. 11, announced the initiation of a randomized, open label Phase 2 clinical study of Ad-RTS IL-12 in combination with palifosfamide to treat patients with non-resectable recurrent or metastatic breast cancer. The two-part, multi-center U.S. study will enroll up to 68 patients with non-resectable, recurrent or metastatic breast cancer who have visible lesions or lesions accessible by injection.

Get latest News, Updates on ZIOP Here

About ThePennyStockProfiler.com
ThePennyStockProfiler.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. ThePennyStockProfiler.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed "informational edge" which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at http://www.ThePennyStockProfiler.com

Disclaimer
The assembled information disseminated by ThePennyStockProfiler.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. ThePennyStockProfiler.com does expect that investors will buy and sell securities based on information assembled and presented in phd-trading.com. PLEASE always do your own due diligence, and consult your financial advisor.